New Podcast CE/CME Alert: "Medications for Opioid Use Disorder" is now available! Listen for FREE now. Subscribers can earn CE credits just for listening and passing a short quiz.

Expert-based medication knowledge at your fingertips! More CE, more resources, more value. Choose your Prescriber Insights membership and get the tools you need for success today. Subscribe Now

Don't Jump to Kerendia for Diabetic Kidney Disease

October 2021

Kerendia (finerenone) will be a new Rx for patients with chronic kidney disease (CKD) due to type 2 diabetes.

It's the first "nonsteroidal mineralocorticoid receptor antagonist"...and is approved to slow kidney disease progression and improve CV outcomes in these patients.

Kerendia is thought to limit fibrosis and inflammation in the kidneys and heart...by blocking effects of aldosterone.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote